Treatment of Human B-Cell Lymphomas Using Minicircle DNA Vector Expressing Anti-CD3/CD20 in a Mouse Model

Human Gene Therapy

Volumn 28, Issue 2, 2017, Pages 216-225

  Pang, Xiaojuan ^a   Ma, Fei ^b,c   Zhang, Peifa ^a   Zhong, Yujian ^a   Zhang, Jing ^b   Wang, Tianyan ^a   Zheng, Gang ^a   Hou, Xiaohu ^a   Zhao, Jing ^a   He, Chengyi ^a   Chen, Zhi Ying ^a  

^a University Town of Shenzhen   (China)

^b Shenzhen Sunsmile Biotechnology Co Ltd   (China)

^c THE SIXTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

B cell lymphomas; BsAb; MC.CD20; minicircle

Indexed keywords

CD20 ANTIBODY; CD3 ANTIBODY; MINICIRCLE DNA; BISPECIFIC ANTIBODY; CD20 ANTIGEN; CD3 ANTIGEN; CIRCULAR DNA; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; B-CELL LYMPHOMA CELL LINE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOMEGALOVIRUS; DNA VECTOR; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN CELL; HYDRODYNAMICS; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; PROTEIN BINDING; PROTEIN EXPRESSION; STIMULATION; TUMOR XENOGRAFT; ADMINISTRATION AND DOSAGE; ANIMAL; DISEASE MODEL; GENE VECTOR; GENETIC ENGINEERING; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOMA, B-CELL;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTIGENS, CD3; DISEASE MODELS, ANIMAL; DNA, CIRCULAR; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; LYMPHOMA, B-CELL; MICE;

EID: 85012154135     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2016.122     Document Type: Article

References (36)

1. Nagorsen D, Kufer P, Baeuerle PA, et al. Blinatumomab: a historical perspective. Pharmacol Ther 2012;136:334-342.
2. Portell CA, Wenzell CM, Advani AS. Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. Clin Pharmacol 2013;5:5-11.
3. Feldman SA, Assadipour Y, Kriley I, et al. Adoptive cell therapy-tumor-infiltrating lymphocytes, Tcell receptors, and chimeric antigen receptors. Semin Oncol 2015;42:626-639.
4. Wang Y, Zhang WY, Han QW, et al. Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. Clin Immunol 2014;155:160-175.
5. Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a Phase Ib study. J Clin Oncol 2016;34:2698-2704.
6. Chen ZY, Ma F, Huang H, et al. Synthetic immunity to break down the bottleneck of cancer immunotherapy. Sci Bull 2015;60:977-985.
7. Fan G, Wang Z, Hao M, et al. Bispecific antibodies and their applications. J Hematol Oncol 2015;8:130.
8. Batlevi CL, Matsuki E, Brentjens RJ, et al. Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol 2016;13:25-40.
9. Eissler N, Ruf P, Mysliwietz J, et al. Trifunctional bispecific antibodies induce tumor-specific T cells and elicit a vaccination effect. Cancer Res 2012;72:3958-3966.
10. Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cellengaging antibody. Science 2008;321:974-977.
11. Xiong D, Xu Y, Liu H, et al. Efficient inhibition of human B-cell lymphoma xenografts with an anti- CD20 ? anti-CD3 bispecific diabody. Cancer Lett 2002;177:29-39.
12. Liu X, Barrett DM, Jiang S, et al. Improved antileukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice. Blood Cancer J 2016;6:e430.
13. Velasquez MP, Torres D, Iwahori K, et al. T cells expressing CD19-specific engager molecules for the immunotherapy of CD19-positive malignancies. Sci Rep 2016;6:27130.
14. Shen W, Du R, Li J, et al. TIFA suppresses hepatocellular carcinoma progression via MALT1- dependent and -independent signaling pathways. Signal Transduct Target Ther 2016;1:16013.
15. Offner S, Hofmeister R, Romaniuk A, et al. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol 2006;43:763-771.
16. Moon EK, Wang LC, Dolfi DV, et al. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. Clin Cancer Res 2014;20:4262-4273.
17. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. New Engl J Med 2013;368:1509-1518.
18. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptortransduced T cells. Blood 2012;119:2709-2720.
19. Klinger M, Benjamin J, Kischel R, et al. Harnessing T cells to fight cancer with BiTE(R) antibody constructs-past developments and future directions. Immunol Rev 2016;270:193-208.
20. Schlereth B, Fichtner I, Lorenczewski G et al. Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/ CD3-bispecific antibody construct. Cancer Res 2005;65:2882-2889.
21. Iwahori K, Kakarla S, Velasquez MP et al. Engager T cells: a new class of antigen-specific T cells that redirect bystander T cells. Mol Ther 2015;23:171-178.
22. Chen ZY, He CY, Ehrhardt A, et al. Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther 2003;8:495-500.
23. Kay MA, He CY, Chen ZY. A robust system for production of minicircle DNA vectors. Nat Biotechnol 2010;28:1287-1289.
24. Munye MM, Tagalakis AD, Barnes JL, et al. Minicircle DNA provides enhanced and prolonged transgene expression following airway gene transfer. Sci Rep 2016;6:23125.
25. Chen ZY, He CY, Kay MA. Improved production and purification of minicircle DNA vector free of plasmid bacterial sequences and capable of persistent transgene expression in vivo. Hum Gene Ther 2005;16:126-131.
26. Kay MA. State-of-the-art gene-based therapies: the road ahead. Nat Rev Genet 2011;12:316-328.
27. Zhang W-Y, Wang Y, Guo Y-L, et al. Treatment of CD20-directed chimeric antigen receptor-modified T cells in patients with relapsed or refractory Bcell non-Hodgkin lymphoma: an early Phase IIa trial report. Signal Transduct Target Ther 2016; 1:16002.
28. Staerz UD, Kanagawa O, Bevan MJ. Hybrid antibodies can target sites for attack by T cells. Nature 1985;314:628-631.
29. Song H, Su X, Yang K, et al. CD20 antibodyconjugated immunoliposomes for targeted chemotherapy of melanoma cancer initiating cells. J Biomed Nanotechnol 2015;11:1927-1946.
30. Klebanoff CA, Rosenberg SA, Restifo NP. Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat Med 2016;22:26-36.
31. Stronen E, Toebes M, Kelderman S, et al. Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science 2016;352:1337-1341.
32. Tran E, Ahmadzadeh M, Lu YC, et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 2015;350:1387-1390.
33. Tran E, Turcotte S, Gros A, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014;344:641-645.
34. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003;302:415-419.
35. Osborn MJ, Webber BR, Knipping F, et al. Evaluation of TCR gene editing achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases. Mol Ther 2016;24:570-581.
36. Buscail L, Bournet B, Vernejoul F, et al. First-inman phase 1 clinical trial of gene therapy for advanced pancreatic cancer: safety, biodistribution, and preliminary clinical findings. Mol Ther 2015;23:779-789.